Emerging treatments for bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer
Intravesical bacillus Calmette–Guérin (BCG) immunotherapy has been the gold standard adjuvant treatment for intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBT). BCG immunotherapy prevents disease recurrence and progression to...
Main Authors: | Hyung Suk Kim, Ho Kyung Seo |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Urological Association
2021-07-01
|
Series: | Investigative and Clinical Urology |
Subjects: | |
Online Access: | https://www.icurology.org/pdf/10.4111/icu.20200602 |
Similar Items
-
Bacillus Calmette–Guérin and Bladder Cancer
by: Azad H.A. Razack
Published: (2007-10-01) -
Granulomatous Hepatitis Following Intra-Vesical Instillation of Bacillus Calmette–Guérin for Treatment of Bladder Cancer
by: Elsa Alves Branco, et al.
Published: (2021-07-01) -
Bacillus Calmette-Guerin Increases Base Excision Repair in Bladder Cancer Cells
by: Selçuk Keskin, et al.
Published: (2021-03-01) -
Single course of intravesical Bacillus Calmette–Guerin versus single course with maintenance therapy in the management of nonmuscle invasive bladder cancer: A prospective randomized study
by: Mohamed Bakr Mohamed, et al.
Published: (2020-01-01) -
Regression of the Sweet's syndrome after Bacillus Calmette-Guérin therapy: A bladder cancer case report
by: İbrahim Halil Baloglu, et al.
Published: (2020-07-01)